S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:OLMA

Olema Pharmaceuticals (OLMA) Stock Forecast, Price & News

$6.55
+0.50 (+8.26%)
(As of 05:22 PM ET)
Compare
Today's Range
$6.03
$6.68
50-Day Range
$3.22
$7.27
52-Week Range
$2.19
$7.45
Volume
201,206 shs
Average Volume
177,470 shs
Market Capitalization
$266.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.25

Olema Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
132.8% Upside
$15.25 Price Target
Short Interest
Bearish
2.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$30,200 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.79) to ($2.92) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

450th out of 981 stocks

Pharmaceutical Preparations Industry

212th out of 476 stocks


OLMA stock logo

About Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Receive OLMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OLMA Stock News Headlines

Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Olema Pharmaceuticals GAAP EPS of -$0.65 in-line
OLMA
See More Headlines

OLMA Price History

OLMA Company Calendar

Last Earnings
5/09/2023
Today
6/08/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OLMA
Fax
N/A
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.25
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+132.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-104,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.90 per share

Miscellaneous

Free Float
31,183,000
Market Cap
$266.98 million
Optionable
Not Optionable
Beta
2.32

Key Executives

  • Dr. Sean P. Bohen M.D. (Age 56)
    Ph.D., Pres, CEO & Director
    Comp: $999.3k
  • Mr. Shane William Charles Kovacs M.B.A. (Age 49)
    Chief Operating & Financial Officer
    Comp: $875.55k
  • Dr. Cyrus L. Harmon Ph.D. (Age 52)
    Chief Research Officer & Director
  • Mr. Kinney HornMr. Kinney Horn (Age 49)
    Chief Bus. Officer
    Comp: $588.3k
  • Dr. Peter J. Kushner Ph.D. (Age 84)
    Co-Founder & Sr. Research Fellow
  • Ms. Courtney Dugan
    VP of Investor Relations & Communications
  • Mr. John B. Moriarty Jr. (Age 55)
    Exec. VP, Chief Legal Officer & Corp. Sec.
  • Ms. Julie Dexter
    VP & Head of People
  • Dr. David C. Myles Ph.D. (Age 60)
    Chief Discovery & Non-Clinical Devel. Officer
  • Ms. Demiana Faltaos Ph.D.
    Pharm.D., VP & Head of Clinical Pharmacology













OLMA Stock - Frequently Asked Questions

Should I buy or sell Olema Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Olema Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OLMA shares.
View OLMA analyst ratings
or view top-rated stocks.

What is Olema Pharmaceuticals' stock price forecast for 2023?

5 analysts have issued 12 month price targets for Olema Pharmaceuticals' stock. Their OLMA share price forecasts range from $11.00 to $20.00. On average, they predict the company's stock price to reach $15.25 in the next twelve months. This suggests a possible upside of 132.8% from the stock's current price.
View analysts price targets for OLMA
or view top-rated stocks among Wall Street analysts.

How have OLMA shares performed in 2023?

Olema Pharmaceuticals' stock was trading at $2.45 at the beginning of 2023. Since then, OLMA shares have increased by 167.3% and is now trading at $6.55.
View the best growth stocks for 2023 here
.

When is Olema Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our OLMA earnings forecast
.

How were Olema Pharmaceuticals' earnings last quarter?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.04.

When did Olema Pharmaceuticals IPO?

(OLMA) raised $170 million in an initial public offering on Thursday, November 19th 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity acted as the underwriters for the IPO.

What is Olema Pharmaceuticals' stock symbol?

Olema Pharmaceuticals trades on the NASDAQ under the ticker symbol "OLMA."

Who are Olema Pharmaceuticals' major shareholders?

Olema Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (2.45%), Sectoral Asset Management Inc. (2.45%), Geode Capital Management LLC (0.86%), Vontobel Holding Ltd. (0.83%), Renaissance Technologies LLC (0.63%) and Deutsche Bank AG (0.63%). Insiders that own company stock include Bvf Partners L P/Il, Cormorant Asset Management, Lp, Cyrus Harmon, G Walmsley Graham, Kinney Horn and Sean Bohen.
View institutional ownership trends
.

How do I buy shares of Olema Pharmaceuticals?

Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Olema Pharmaceuticals' stock price today?

One share of OLMA stock can currently be purchased for approximately $6.55.

How much money does Olema Pharmaceuticals make?

Olema Pharmaceuticals (NASDAQ:OLMA) has a market capitalization of $266.98 million. The company earns $-104,790,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis.

How can I contact Olema Pharmaceuticals?

Olema Pharmaceuticals' mailing address is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. The official website for the company is www.olema.com. The company can be reached via phone at 650-243-5555 or via email at ir@olema.com.

This page (NASDAQ:OLMA) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -